Genfit SA logo
Genfit SA GNFT

Annual report 2024
added 03-21-2026

report update icon

Genfit SA EPS Ratio 2011-2026 | GNFT

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Genfit SA

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - 1.51 -2.6 -1.76 -2.55 -1.79 - - - - - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
1.51 -2.6 -1.44

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-15.4 - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
-3.87 - 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-0.07 - 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
-1.77 - -0.23 % $ 916 M usaUSA
Lipocine Lipocine
LPCN
-3.1 $ 7.4 1.23 % $ 39 M usaUSA
I-Mab I-Mab
IMAB
-7.66 - - $ 866 M chinaChina
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.51 - 10.36 % $ 9.8 M usaUSA
Biophytis SA Biophytis SA
BPTS
-0.26 - -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-8.28 $ 217.23 -0.38 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
-31 - -18.52 % $ 27.3 M britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
2.1 $ 19.47 1.25 % $ 910 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-0.36 - - $ 26.5 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
-5.9 $ 8.28 -1.84 % $ 110 M usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
-0.14 $ 1.68 2.13 % $ 610 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
-13.7 - -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
-204 - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
-0.79 - 4.01 % $ 150 M canadaCanada
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
-1.45 $ 0.74 21.89 % $ 8.48 M israelIsrael
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-6.62 - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-1.66 - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
-7.99 - -9.65 % $ 45.9 M usaUSA
Exelixis Exelixis
EXEL
2.88 $ 41.51 0.23 % $ 11.3 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-15.8 - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-0.86 $ 1.36 -3.21 % $ 347 M britainBritain
Mesoblast Limited Mesoblast Limited
MESO
-0.141 $ 14.31 2.07 % $ 9.29 B australiaAustralia
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-2.46 - - $ 7.46 M israelIsrael
ChemoCentryx ChemoCentryx
CCXI
-1.89 - - $ 3.74 B usaUSA
Genmab A/S Genmab A/S
GMAB
34.4 $ 25.73 0.19 % $ 16.5 B danmarkDanmark
Aytu BioScience Aytu BioScience
AYTU
-2.16 $ 2.61 -0.76 % $ 16.4 M usaUSA
Atreca Atreca
BCEL
-2.52 - -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
0.85 - -4.8 % $ 255 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-24.9 - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-2.21 - - $ 867 M germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
0.2 - 0.49 % $ 251 B cayman-islandsCayman-islands
Immatics N.V. Immatics N.V.
IMTX
-4.77 $ 9.19 -3.36 % $ 578 M germanyGermany
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-2.08 - -74.18 % $ 955 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-3.75 - - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-0.17 $ 4.34 -1.92 % $ 832 M canadaCanada
Akouos Akouos
AKUS
-2.52 - 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-2.38 - 1.93 % $ 17.4 M usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
-1.41 $ 69.55 -1.75 % $ 11.1 B usaUSA
Allakos Allakos
ALLK
-2.14 - - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
-1.06 - -5.38 % $ 6.06 M usaUSA
Longeveron Longeveron
LGVN
-1.29 $ 0.87 -8.8 % $ 15.3 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-0.72 - 3.16 % $ 1.9 M usaUSA